SEC Filing Analysis: TScan Therapeutics, Inc. (TCRX)

Executive Summary

• Trading Significance: Medium
• Key Takeaway: Chief Legal and Strategy Officer Zoran Zdraveski received an RSU grant of 300,000 shares, representing 0.46% of total shares outstanding.
• Market Impact: Neutral; routine compensation event structured with milestone-based clinical trial vesting.

Company Information

Field	Value
Company	TScan Therapeutics, Inc.
Ticker Symbol	TCRX
CIK	0001783328
Industry	Biological Products (No Diagnostic Substances)

Insider Information

Field	Value
Name	Zoran Zdraveski
CIK	0001741285
Title/Position	Chief Legal and Strategy Officer
Relationship	Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2026-10-01
Transaction Code	A (Award/Grant)
Security Type	Voting Common Stock
Shares Involved	300,000
Price Per Share	$0.00
Total Value	$0.00
Shares Owned After	304,716
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$0.00
% of Market Cap	0.00%
Shares Transacted	300,000
% of Shares Outstanding	0.46%
Post-Transaction Ownership	304,716 shares (0.47% of outstanding)
Materiality Assessment	Significant based on share count percentage

Impact Evaluation

• Market Cap Context: For a micro-cap biotechnology company valued at approximately $20M, a 300,000 share grant represents a noticeable portion (0.46%) of the 65.35M shares outstanding.
• Ownership Concentration: The award significantly increases the insider's reported beneficial ownership from 4,716 to 304,716 shares, elevating insider stake to 0.47% of total shares outstanding.
• Dilution Impact: The potential dilution of 0.46% is moderate and deferred over a multi-year vesting schedule tied to clinical performance.
• Transaction Significance: While cash value transacted is zero, the share volume relative to the issuer's total share base places this transaction in the medium significance category.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: This is an equity incentive compensation grant rather than an open-market purchase or sale. The milestone vesting structure ties executive compensation directly to clinical progress.

Volume & Sentiment

• Expected Volume Impact: Negligible immediate impact on open-market trading volume.
• Sentiment Indicator: Neutral; executive compensation aligned with pipeline milestones.

Additional Context

Transaction Notes

• Timing: Effective October 1, 2026.
• Special Circumstances: 25% of the restricted stock units vest on September 30, 2028; the remaining 75% vest on the earlier of reporting completion of the pivotal trial of TSC-101 or September 30, 2030, subject to continuous service.